HDAC9 and cancer: A new paper by Carta et al [150] has suggested that histone deacetylase (HDAC) inhibitors (novel agents currently being developed as pleiotropic anti-cancer agents) may have potential for development as anti-inflammatory agents as they reduced ATP-stimulated IL-1β production via the P2X7R. The potential role of P2X7R ligands in the treatment of cancer appears exciting and will undoubtedly be the subject of many future investigations.